ReviewBioMed research international2026
Bacteriocins as a Promising Antimicrobial Strategy Against Multidrug-Resistant Pathogens: Mechanisms of Action, Applications in Human and Animal Health, and the Food Industry.
Review in BioMed research international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global rise of antimicrobial resistance has significantly increased the difficulty treating infectious agents, creating an urgent need for alternative therapeutic strategies. In this context, bacteriocins have emerged as a promising solution, offering a potential alternative to conventional antibacterial therapies. This review explores the potential application of bacteriocins in combating pathogenic bacteria across various sectors, including healthcare and the food industry, while also highlighting mechanisms of action. Bacteriocins are antimicrobial peptides produced ribosomally by certain bacteria and archaea, capable of inhibiting the growth of similar pathogens through distinct modes of action. These peptides have been utilized in both human and veterinary medicine, as well as in agriculture, where they help in preventing unwanted growth of microorganisms. In veterinary practice, bacteriocins are incorporated into products such as udder disinfectants for dairy cattle and topical dermatological formulations for dogs, cats, and horses. Given their broad range of applications, bacteriocins warrant greater consideration by clinicians, veterinarians and industry stakeholders for the prevention and control of microbial infections. Nevertheless, the implementation of robust surveillance systems is crucial for curbing the spread of multidrug-resistant pathogens, rather than relying solely on conventional antibiotic therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.